StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ELDN yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $3.90 | $3.80 | -2.56% | 1.0M |
| 05-18 | $3.80 | $3.58 | -5.79% | 1.1M |
| 05-19 | $3.54 | $3.58 | +1.13% | 0.9M |
| 05-20 | $3.55 | $3.84 | +8.17% | 0.9M |
| 05-21 | $3.79 | $3.92 | +3.56% | 0.6M |
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2016 2016-12-31 | Annual 2015 2015-12-31 |
|---|---|---|
Revenue | $0.00 | $0.00 |
Operating Income | $-5.13M | $-45.26M |
Net Income | $-5.66M | $-45.09M |
EPS (Diluted) | Not available | Not available |
Total Assets | $1.20M | $67.97M |
Total Liabilities | $3.90M | $6.25M |
Cash & Equivalents | $1.10M | $24.02M |
Free Cash Flow OCF − CapEx | $-4.93M | $-41.80M |
Shares Outstanding | 394.31K | 22.60M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.